ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive outlook with strategic expansions, improved payer access, and a strong international presence. Despite some lack of clarity in management's responses, there is confidence in achieving breakeven by mid-2027 and significant market share growth. The absence of a market cap suggests a potential strong reaction, but overall, the strategic initiatives and positive guidance point to a likely positive stock price movement in the short term.
Key Financial Performance
Total Revenue $22.7 million in Q1 2026, including $17.5 million in U.S. net product revenue for neffy. This represents 3x the volume of neffy prescriptions year-over-year and more than double the revenue. The growth is attributed to improved payer access, reduced prescribing friction, and maturation in refill cycles.
Revenue from Collaboration Agreements $2.5 million in Q1 2026. This includes part of a $5 million milestone payment from ALK triggered by the approval of neffy 1 milligram in the EU.
Supply Revenue from International Partners $2.7 million in Q1 2026. This revenue is part of the total revenue generated from international collaborations.
R&D Expenses $4.3 million in Q1 2026. This reflects continued investment in development programs, including the chronic spontaneous urticaria study.
SG&A Expenses $72.2 million in Q1 2026. This reflects commercialization investments across direct-to-consumer (DTC) and field execution. The focus is shifting from infrastructure build to optimizing spend toward the highest return commercial activities.
Gross to Net Retention Low to mid-50% range in Q1 2026, targeting approximately 50% at a steady state. The economics underlying the CVS Caremark proposal align with the long-term gross to net retention target.
Cash, Cash Equivalents, and Short-term Investments $201 million at the end of Q1 2026. This provides flexibility to support commercial execution, pipeline advancements, and progress toward cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue from neffy: Generated $17.5 million in U.S. net product revenue for neffy in Q1 2026, representing 3x the volume of prescriptions year-over-year and more than double the revenue.
FDA label update: Minimum age restriction removed, enabling pediatric patients greater than 33 pounds and under 4 years of age to access treatment.
International approvals: Health Canada approved neffy as the first needle-free emergency treatment for allergic reactions, with commercial launch planned for later in 2026. European Commission granted marketing authorization for Euro neffy 1 milligram.
Market expansion in Medicaid: Secured unrestricted coverage for neffy in 9 states, including Florida, with plans to expand to the majority of Medicaid programs by early 2027.
CVS Caremark proposal: Submitted an updated proposal to CVS Caremark to add neffy to their commercial formularies without prior authorization, targeting a July 1 effective date.
Sales force expansion: Expanded sales force to 148 representatives to prioritize high-volume prescribing practices and improve engagement.
Affordability initiative: Introduced a $199 retail pharmacy cash price program to reduce out-of-pocket costs for patients with rejected commercial claims.
Focus on reducing prescribing friction: Implemented initiatives to address prior authorization barriers and simplify prescribing processes for healthcare providers.
Direct-to-consumer marketing: Increased targeted media campaigns to drive awareness and adoption, particularly among parents and older demographics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Prior Authorization Process: The prior authorization process creates friction that delays or deters prescribing, impacting prescriber adoption and patient access.
High Out-of-Pocket Costs: Patients without insurance coverage faced high out-of-pocket costs, sometimes exceeding $1,000, which created confusion and impacted prescribing decisions.
CVS Caremark Approval Delays: The CVS Caremark formulary approval process has been extended due to PBM focus on new legislation and FTC-related interactions, delaying expanded access for patients.
Medicaid Coverage Limitations: Medicaid coverage for neffy still requires prior authorizations in many states, limiting access for a significant portion of the epinephrine market.
Market Dynamics and Prescribing Friction: The mature refill-driven market and reliance on new in-office prescriptions create challenges for scaling adoption and achieving consistent growth.
High SG&A Expenses: Significant SG&A expenses for commercialization efforts, including sales force expansion and direct-to-consumer marketing, may strain financial resources.
Dependency on Seasonal Demand: Revenue and prescription growth are heavily weighted toward the back-to-school season, creating potential volatility in financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expansion of neffy access: The company expects neffy prescription growth to expand with new initiatives aimed at reducing provider and patient friction. A favorable CVS Caremark decision, expected by July 1, 2026, would further accelerate this trajectory.
Improved affordability for neffy: A new program allows patients with rejected commercial claims to pay no more than $199 at retail pharmacies, which is expected to increase prescriptions and align healthcare provider perceptions with actual costs.
Back-to-school season impact: The company anticipates increased prescribing patterns and refill contributions during the back-to-school season, which is typically the busiest period for prescriptions.
Pediatric adoption: The removal of the minimum age restriction by the FDA is expected to accelerate pediatric adoption of neffy, particularly for children under 4 years of age.
International market expansion: Health Canada approved neffy for commercial launch later in 2026, and the European Commission granted marketing authorization for Euro neffy 1 milligram, extending access in the European region.
Medicaid coverage expansion: The company expects to achieve unrestricted Medicaid coverage in the majority of states by early 2027, which would significantly expand access to neffy.
Sales force expansion: The sales force was expanded to 148 representatives in May 2026 to deepen reach within high-volume prescribing practices and support adoption.
Revenue expectations: Revenue is expected to be weighted toward the second half of 2026 due to back-to-school season, evolving prescribing patterns, and early refill dynamics.
Gross-to-net retention target: The company continues to target a gross-to-net retention rate of approximately 50% at a steady state.
Path to profitability: The company is focused on building a predictable commercial franchise with disciplined spending and a clear path to profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the level of conviction regarding CVS coverage and removing prior authorizations by July 1?
A:The management expressed confidence in the approval process with CVS Caremark, which represents 15% of covered lives. They believe the updated proposal aligns with the July 1 start and are focusing marketing efforts on the top 12,000 physicians who represent about 50% of prescriptions.
Q:What magnitude of lift is expected from refills later this year and in 2027?
A:Management expects renewal prescriptions over the summer to contribute to the peak season. They anticipate a lift as parents renew prescriptions for the full school year, with trends continuing into 2027.
Q:When is broader prescribing expected to expand to lower decile accounts?
A:Management noted that broadening is already happening, with over 28,000 physicians prescribing the product. They are focusing on high-volume accounts but also seeing traction in lower decile accounts through advertising and non-personal promotion.
Q:What is the expectation for market share growth into the summer?
A:Management expects meaningful market share growth, projecting to be on track with consensus even without Caremark. They are confident in week-over-week and month-over-month growth, supported by streamlined prescribing and an expanded sales force.
Q:Have there been any positive metrics in penetrating the electronic refill market?
A:Efforts are ongoing, focusing on establishing processes with office staff and implementing smart phrases in EHR systems. These measures aim to interrupt the refill process and promote the product.
Q:Are there updates on smaller commercial plans outside of CVS Caremark?
A:Management is focusing on Blue Cross companies and Medicaid, with progress being made to secure additional state Blue Cross companies before the summer season.
Q:What is the strategy for raising awareness among physicians post-Caremark deal?
A:The strategy includes informing doctors about coverage changes, providing tools for prescribing, and aligning marketing and sales teams. They are ready to implement these measures quickly once the deal is finalized.
Q:How does the automated conversion process for denied claims work, and what impact is expected?
A:The process, recently implemented, converts denied claims at the pharmacy level to a $199 price, avoiding high retail prices. This is expected to reduce abandonment rates and negative feedback to doctors, simplifying the prescribing process.
Q:How does the company plan to achieve breakeven by mid-2027 given the current burn rate?
A:Management projects breakeven by mid-2027, with losses decreasing over time. They plan to reallocate funding to higher ROI activities and potentially cut expenses. The first quarter is historically the worst for sales, but they expect improvement in the second half of the year.
Q:What was the royalty payment from ALK in the first quarter?
A:The royalty payment from ALK was less than $100,000, as they are just starting their run rate in multiple countries. Growth is expected in the future.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical details on the magnitude of lift expected from refills later this year and in 2027. Additionally, they did not provide clear metrics or timelines for the penetration of the electronic refill market. The response to the question about achieving breakeven by mid-2027 lacked detailed financial projections or a breakdown of cost-cutting measures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CVS process
CVS proposal
Florida
HCPs
Medicaid
Zinc
access affordability
access prescribing
addition
adoption consumer
anaphylaxis
approval process
authorization state
base
cash price
category
claim
dynamic
ease prescribing
epinephrine market
evolution
friction prescribing
improvement access
injector product
medium
pharmacy cash
pocket
prescriber
prescribing decile
prescribing pattern
price pharmacy
proportion life
proposal stage
refill
request
school nurse
school season
staff
stage approval
visit
SPRY Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects a positive outlook with strategic expansions, improved payer access, and a strong international presence. Despite some lack of clarity in management's responses, there is confidence in achieving breakeven by mid-2027 and significant market share growth. The absence of a market cap suggests a potential strong reaction, but overall, the strategic initiatives and positive guidance point to a likely positive stock price movement in the short term.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed outlook. Financial performance is stable with positive revenue growth and a solid cash balance. However, challenges exist in regulatory and coverage hurdles, and SG&A expenses are high. The Q&A reveals some concerns about inventory dynamics and the unclear timeline for unrestricted access. Despite strategic initiatives and global expansion plans, the overall sentiment remains neutral due to the lack of immediate catalysts and ongoing uncertainties in coverage and market expansion.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Positive11-10
The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A indicate strong growth in Neffy's sales and positive market reception, demonstrated by a 64% increase in revenue and increased prescriptions. The DTC campaign is expected to further drive growth. However, there is some concern about the ceiling for commercial coverage without prior authorization. Despite this, the overall sentiment is positive due to strong financial performance and optimistic future guidance.
SPRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
